Creabilis adds three executives to management team
Reflects growing confidence in pipeline and science that underpins it
Alex Leech joins as vice president, head of finance and operations, James Sandy as senior vice president, head of development, and Peter Spargo as senior vice president for chemistry manufacturing and controls (CMC).
Leech was most recently head of operations at Solace Pharmaceuticals. Prior to this, he worked for the Pfizer r&d organisation where he was head of European project management. He has also held a number of operational and engineering management roles at Ford. Sandy was most recently at Pfizer as development team leader of Pfizer’s GI portfolio. Prior to working at Pfizer, he was head of biometrics at Astra UK.
Spargo was most recently at Novexel as senior vice president of CMC. Prior to this he was head of chemical process r&d for Pfizer in Europe.
Eliot Forster, ceo of Creabilis, said: ‘This expansion of our senior management team reflects Creabilis’ growing maturity and the confidence we have in our pipeline, our science and the culture that underpins it.’
You may also like
Research & Development
Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases
The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
Manufacturing
Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics
Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Formulation meets function: addressing palatability in drug development (part II)
Part I of this article examined the critical role of palatability in patient adherence to treatment regimens, the underlying biological challenges of bitterness in medications and the innovative strategies used to create more acceptable and effective drug formulations